Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 336 entries
Sorted by: Best Match Show Resources per page
Erratum to: Prognostic significance of stem cell marker CD133 determined by promoter methylation but not by immunohistochemical expression in malignant gliomas.

Journal of neuro-oncology

Wu X, Wu F, Xu D, Zhang T.
PMID: 26915103
J Neurooncol. 2016 Apr;127(2):233. doi: 10.1007/s11060-016-2089-x.

No abstract available.

Cite
Wu X, Wu F, Xu D, et al. Erratum to: Prognostic significance of stem cell marker CD133 determined by promoter methylation but not by immunohistochemical expression in malignant gliomas. J Neurooncol. 2016;127(2):233doi: 10.1007/s11060-016-2089-x.
Wu, X., Wu, F., Xu, D., & Zhang, T. (2016). Erratum to: Prognostic significance of stem cell marker CD133 determined by promoter methylation but not by immunohistochemical expression in malignant gliomas. Journal of neuro-oncology, 127(2), 233. https://doi.org/10.1007/s11060-016-2089-x
Wu, Xing, et al. "Erratum to: Prognostic significance of stem cell marker CD133 determined by promoter methylation but not by immunohistochemical expression in malignant gliomas." Journal of neuro-oncology vol. 127,2 (2016): 233. doi: https://doi.org/10.1007/s11060-016-2089-x
Wu X, Wu F, Xu D, Zhang T. Erratum to: Prognostic significance of stem cell marker CD133 determined by promoter methylation but not by immunohistochemical expression in malignant gliomas. J Neurooncol. 2016 Apr;127(2):233. doi: 10.1007/s11060-016-2089-x. PMID: 26915103; PMCID: PMC4969914.
Copy Download .nbib Format: NLM
Spontaneous pneumocephalus associated with a melanoma brain metastasis: a Case Report.

Journal of neuro-oncology

Ahn J, Bunevicius A, Sheehan J.
PMID: 33687627
J Neurooncol. 2021 May;152(3):617-619. doi: 10.1007/s11060-021-03728-4. Epub 2021 Mar 09.

No abstract available.

Cite
Ahn J, Bunevicius A, Sheehan J. Spontaneous pneumocephalus associated with a melanoma brain metastasis: a Case Report. J Neurooncol. 2021;152(3):617-619doi: 10.1007/s11060-021-03728-4.
Ahn, J., Bunevicius, A., & Sheehan, J. (2021). Spontaneous pneumocephalus associated with a melanoma brain metastasis: a Case Report. Journal of neuro-oncology, 152(3), 617-619. https://doi.org/10.1007/s11060-021-03728-4
Ahn, JungEun, et al. "Spontaneous pneumocephalus associated with a melanoma brain metastasis: a Case Report." Journal of neuro-oncology vol. 152,3 (2021): 617-619. doi: https://doi.org/10.1007/s11060-021-03728-4
Ahn J, Bunevicius A, Sheehan J. Spontaneous pneumocephalus associated with a melanoma brain metastasis: a Case Report. J Neurooncol. 2021 May;152(3):617-619. doi: 10.1007/s11060-021-03728-4. Epub 2021 Mar 09. PMID: 33687627.
Copy Download .nbib Format: NLM
Long-term disease control and treatment outcomes of stereotactic radiosurgery in cavernous sinus meningiomas.

Journal of neuro-oncology

Martinez-Perez R, Florez-Perdomo W, Freeman L, Ung TH, Youssef AS.
PMID: 33772678
J Neurooncol. 2021 May;152(3):439-449. doi: 10.1007/s11060-021-03732-8. Epub 2021 Mar 27.

BACKGROUND: Most of the current knowledge on the clinical effects of stereotactic radiosurgery (SRS) on the treatment of cavernous sinus meningiomas (CSM) is based on series with limited follow-up. However, determining the role of radiation in a tumor with...

Cite
Martinez-Perez R, Florez-Perdomo W, Freeman L, et al. Long-term disease control and treatment outcomes of stereotactic radiosurgery in cavernous sinus meningiomas. J Neurooncol. 2021;152(3):439-449doi: 10.1007/s11060-021-03732-8.
Martinez-Perez, R., Florez-Perdomo, W., Freeman, L., Ung, T. H., & Youssef, A. S. (2021). Long-term disease control and treatment outcomes of stereotactic radiosurgery in cavernous sinus meningiomas. Journal of neuro-oncology, 152(3), 439-449. https://doi.org/10.1007/s11060-021-03732-8
Martinez-Perez, Rafael, et al. "Long-term disease control and treatment outcomes of stereotactic radiosurgery in cavernous sinus meningiomas." Journal of neuro-oncology vol. 152,3 (2021): 439-449. doi: https://doi.org/10.1007/s11060-021-03732-8
Martinez-Perez R, Florez-Perdomo W, Freeman L, Ung TH, Youssef AS. Long-term disease control and treatment outcomes of stereotactic radiosurgery in cavernous sinus meningiomas. J Neurooncol. 2021 May;152(3):439-449. doi: 10.1007/s11060-021-03732-8. Epub 2021 Mar 27. PMID: 33772678.
Copy Download .nbib Format: NLM
The integrated multiomic diagnosis of sporadic meningiomas: a review of its clinical implications.

Journal of neuro-oncology

Robert SM, Vetsa S, Nadar A, Vasandani S, Youngblood MW, Gorelick E, Jin L, Marianayanam N, Erson-Omay EZ, Günel M, Moliterno J.
PMID: 34846640
J Neurooncol. 2021 Nov 30; doi: 10.1007/s11060-021-03874-9. Epub 2021 Nov 30.

INTRODUCTION: Meningiomas are generally considered "benign," however, these tumors can demonstrate variability in behavior and a surprising aggressiveness with elevated rates of recurrence. The advancement of next-generation molecular technologies have led to the understanding of the genomic and epigenomic...

Cite
Robert SM, Vetsa S, Nadar A, et al. The integrated multiomic diagnosis of sporadic meningiomas: a review of its clinical implications. J Neurooncol. 2021;doi: 10.1007/s11060-021-03874-9.
Robert, S. M., Vetsa, S., Nadar, A., Vasandani, S., Youngblood, M. W., Gorelick, E., Jin, L., Marianayanam, N., Erson-Omay, E. Z., Günel, M., & Moliterno, J. (2021). The integrated multiomic diagnosis of sporadic meningiomas: a review of its clinical implications. Journal of neuro-oncology, . https://doi.org/10.1007/s11060-021-03874-9
Robert, Stephanie M, et al. "The integrated multiomic diagnosis of sporadic meningiomas: a review of its clinical implications." Journal of neuro-oncology vol. (2021). doi: https://doi.org/10.1007/s11060-021-03874-9
Robert SM, Vetsa S, Nadar A, Vasandani S, Youngblood MW, Gorelick E, Jin L, Marianayanam N, Erson-Omay EZ, Günel M, Moliterno J. The integrated multiomic diagnosis of sporadic meningiomas: a review of its clinical implications. J Neurooncol. 2021 Nov 30; doi: 10.1007/s11060-021-03874-9. Epub 2021 Nov 30. PMID: 34846640.
Copy Download .nbib Format: NLM
A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas.

Journal of neuro-oncology

Dixit KS, Sachdev S, Amidei C, Kumthekar P, Kruser TJ, Gondi V, Grimm S, Lukas RV, Nicholas MK, Chmura SJ, Fought AJ, Mehta M, Raizer JJ.
PMID: 34689306
J Neurooncol. 2021 Dec;155(3):297-306. doi: 10.1007/s11060-021-03875-8. Epub 2021 Oct 24.

PURPOSE: Survival is dismal for bevacizumab refractory high-grade glioma patients. We prospectively investigated the efficacy of re-irradiation, bevacizumab, and temozolomide in bevacizumab-naïve and bevacizumab-exposed recurrent high-grade glioma, without volume limitations, in a single arm trial.METHODS: Recurrent high-grade glioma patients...

Cite
Dixit KS, Sachdev S, Amidei C, et al. A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas. J Neurooncol. 2021;155(3):297-306doi: 10.1007/s11060-021-03875-8.
Dixit, K. S., Sachdev, S., Amidei, C., Kumthekar, P., Kruser, T. J., Gondi, V., Grimm, S., Lukas, R. V., Nicholas, M. K., Chmura, S. J., Fought, A. J., Mehta, M., & Raizer, J. J. (2021). A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas. Journal of neuro-oncology, 155(3), 297-306. https://doi.org/10.1007/s11060-021-03875-8
Dixit, Karan S, et al. "A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas." Journal of neuro-oncology vol. 155,3 (2021): 297-306. doi: https://doi.org/10.1007/s11060-021-03875-8
Dixit KS, Sachdev S, Amidei C, Kumthekar P, Kruser TJ, Gondi V, Grimm S, Lukas RV, Nicholas MK, Chmura SJ, Fought AJ, Mehta M, Raizer JJ. A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas. J Neurooncol. 2021 Dec;155(3):297-306. doi: 10.1007/s11060-021-03875-8. Epub 2021 Oct 24. PMID: 34689306.
Copy Download .nbib Format: NLM
Impact of cerebrospinal fluid flow study in patients undergoing intrathecal chemotherapy via ventricular catheter reservoir.

Journal of neuro-oncology

Eltobgy M, Huntoon K, Musgrave N, Shaikhouni A, Hardesty DA, Giglio P, Elder JB.
PMID: 33860429
J Neurooncol. 2021 May;153(1):161-167. doi: 10.1007/s11060-021-03756-0. Epub 2021 Apr 15.

PURPOSE: Leptomeningeal carcinomatosis (LMC) is a form of CNS cancer metastasis with severe morbidity. Intrathecal chemotherapy (ITC) administration through an implanted ventricular catheter reservoir (IVCR) is often utilized. Additionally, a nuclear imaging flow study can be performed prior to...

Cite
Eltobgy M, Huntoon K, Musgrave N, et al. Impact of cerebrospinal fluid flow study in patients undergoing intrathecal chemotherapy via ventricular catheter reservoir. J Neurooncol. 2021;153(1):161-167doi: 10.1007/s11060-021-03756-0.
Eltobgy, M., Huntoon, K., Musgrave, N., Shaikhouni, A., Hardesty, D. A., Giglio, P., & Elder, J. B. (2021). Impact of cerebrospinal fluid flow study in patients undergoing intrathecal chemotherapy via ventricular catheter reservoir. Journal of neuro-oncology, 153(1), 161-167. https://doi.org/10.1007/s11060-021-03756-0
Eltobgy, Mostafa, et al. "Impact of cerebrospinal fluid flow study in patients undergoing intrathecal chemotherapy via ventricular catheter reservoir." Journal of neuro-oncology vol. 153,1 (2021): 161-167. doi: https://doi.org/10.1007/s11060-021-03756-0
Eltobgy M, Huntoon K, Musgrave N, Shaikhouni A, Hardesty DA, Giglio P, Elder JB. Impact of cerebrospinal fluid flow study in patients undergoing intrathecal chemotherapy via ventricular catheter reservoir. J Neurooncol. 2021 May;153(1):161-167. doi: 10.1007/s11060-021-03756-0. Epub 2021 Apr 15. PMID: 33860429.
Copy Download .nbib Format: NLM
Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma?.

Journal of neuro-oncology

Teske N, Karschnia P, Weller J, Siller S, Dorostkar MM, Herms J, von Baumgarten L, Tonn JC, Thon N.
PMID: 34902093
J Neurooncol. 2021 Dec 13; doi: 10.1007/s11060-021-03912-6. Epub 2021 Dec 13.

INTRODUCTION: The cIMPACT-NOW update 6 first introduced glioblastoma diagnosis based on the combination of IDH-wildtype (IDHwt) status and TERT promotor mutation (pTERTmut). In glioblastoma as defined by histopathology according to the WHO 2016 classification, MGMT promotor status is associated...

Cite
Teske N, Karschnia P, Weller J, et al. Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma?. J Neurooncol. 2021;doi: 10.1007/s11060-021-03912-6.
Teske, N., Karschnia, P., Weller, J., Siller, S., Dorostkar, M. M., Herms, J., von Baumgarten, L., Tonn, J. C., & Thon, N. (2021). Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma?. Journal of neuro-oncology, . https://doi.org/10.1007/s11060-021-03912-6
Teske, Nico, et al. "Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma?." Journal of neuro-oncology vol. (2021). doi: https://doi.org/10.1007/s11060-021-03912-6
Teske N, Karschnia P, Weller J, Siller S, Dorostkar MM, Herms J, von Baumgarten L, Tonn JC, Thon N. Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma?. J Neurooncol. 2021 Dec 13; doi: 10.1007/s11060-021-03912-6. Epub 2021 Dec 13. PMID: 34902093.
Copy Download .nbib Format: NLM
Effect of antiepileptic drugs in glioma patients on self-reported depression, anxiety, and cognitive complaints.

Journal of neuro-oncology

van der Meer PB, Koekkoek JAF, van den Bent MJ, Dirven L, Taphoorn MJB.
PMID: 33822293
J Neurooncol. 2021 May;153(1):89-98. doi: 10.1007/s11060-021-03747-1. Epub 2021 Apr 06.

INTRODUCTION: AEDs have been associated with depression, anxiety, and cognitive impairment, all frequent complications of glioma and its subsequent treatment, with considerable morbidity and an adverse effect on health-related quality of life. This study aimed to determine the independent...

Cite
van der Meer PB, Koekkoek JAF, van den Bent MJ, et al. Effect of antiepileptic drugs in glioma patients on self-reported depression, anxiety, and cognitive complaints. J Neurooncol. 2021;153(1):89-98doi: 10.1007/s11060-021-03747-1.
van der Meer, P. B., Koekkoek, J. A. F., van den Bent, M. J., Dirven, L., & Taphoorn, M. J. B. (2021). Effect of antiepileptic drugs in glioma patients on self-reported depression, anxiety, and cognitive complaints. Journal of neuro-oncology, 153(1), 89-98. https://doi.org/10.1007/s11060-021-03747-1
van der Meer, Pim B, et al. "Effect of antiepileptic drugs in glioma patients on self-reported depression, anxiety, and cognitive complaints." Journal of neuro-oncology vol. 153,1 (2021): 89-98. doi: https://doi.org/10.1007/s11060-021-03747-1
van der Meer PB, Koekkoek JAF, van den Bent MJ, Dirven L, Taphoorn MJB. Effect of antiepileptic drugs in glioma patients on self-reported depression, anxiety, and cognitive complaints. J Neurooncol. 2021 May;153(1):89-98. doi: 10.1007/s11060-021-03747-1. Epub 2021 Apr 06. PMID: 33822293; PMCID: PMC8131297.
Copy Download .nbib Format: NLM
The SH3PXD2A-HTRA1 fusion transcript is extremely rare in Norwegian sporadic vestibular schwannoma patients.

Journal of neuro-oncology

Taule-Sivertsen P, Bruland O, Håvik AL, Bratland E, Lund-Johansen M, Knappskog PM.
PMID: 34213706
J Neurooncol. 2021 Aug;154(1):35-40. doi: 10.1007/s11060-021-03796-6. Epub 2021 Jul 02.

INTRODUCTION: Vestibular schwannoma (VS) is a benign intracranial tumor in which the underlying genetics is largely uncertain, apart from mutations in the tumor suppressor gene NF2. Alternative tumorigenic mechanisms have been proposed, including a recurrent in-frame fusion transcript of...

Cite
Taule-Sivertsen P, Bruland O, Håvik AL, et al. The SH3PXD2A-HTRA1 fusion transcript is extremely rare in Norwegian sporadic vestibular schwannoma patients. J Neurooncol. 2021;154(1):35-40doi: 10.1007/s11060-021-03796-6.
Taule-Sivertsen, P., Bruland, O., Håvik, A. L., Bratland, E., Lund-Johansen, M., & Knappskog, P. M. (2021). The SH3PXD2A-HTRA1 fusion transcript is extremely rare in Norwegian sporadic vestibular schwannoma patients. Journal of neuro-oncology, 154(1), 35-40. https://doi.org/10.1007/s11060-021-03796-6
Taule-Sivertsen, Peter, et al. "The SH3PXD2A-HTRA1 fusion transcript is extremely rare in Norwegian sporadic vestibular schwannoma patients." Journal of neuro-oncology vol. 154,1 (2021): 35-40. doi: https://doi.org/10.1007/s11060-021-03796-6
Taule-Sivertsen P, Bruland O, Håvik AL, Bratland E, Lund-Johansen M, Knappskog PM. The SH3PXD2A-HTRA1 fusion transcript is extremely rare in Norwegian sporadic vestibular schwannoma patients. J Neurooncol. 2021 Aug;154(1):35-40. doi: 10.1007/s11060-021-03796-6. Epub 2021 Jul 02. PMID: 34213706; PMCID: PMC8367919.
Copy Download .nbib Format: NLM
Hematological adverse events in the management of glioblastoma.

Journal of neuro-oncology

Garcia CR, Myint ZW, Jayswal R, Wang C, Morgan RM, Butts AR, Weiss HL, Villano JL.
PMID: 34820776
J Neurooncol. 2021 Nov 24; doi: 10.1007/s11060-021-03891-8. Epub 2021 Nov 24.

BACKGROUND: Hematological adverse events (HAEs) are common during treatment for glioblastoma (GBM), usually associated with temozolomide (TMZ). Their clinical value is uncertain, as few investigations have focused on outcomes for HAEs during GBM treatment.METHODS: We combined data from two...

Cite
Garcia CR, Myint ZW, Jayswal R, et al. Hematological adverse events in the management of glioblastoma. J Neurooncol. 2021;doi: 10.1007/s11060-021-03891-8.
Garcia, C. R., Myint, Z. W., Jayswal, R., Wang, C., Morgan, R. M., Butts, A. R., Weiss, H. L., & Villano, J. L. (2021). Hematological adverse events in the management of glioblastoma. Journal of neuro-oncology, . https://doi.org/10.1007/s11060-021-03891-8
Garcia, Catherine R, et al. "Hematological adverse events in the management of glioblastoma." Journal of neuro-oncology vol. (2021). doi: https://doi.org/10.1007/s11060-021-03891-8
Garcia CR, Myint ZW, Jayswal R, Wang C, Morgan RM, Butts AR, Weiss HL, Villano JL. Hematological adverse events in the management of glioblastoma. J Neurooncol. 2021 Nov 24; doi: 10.1007/s11060-021-03891-8. Epub 2021 Nov 24. PMID: 34820776.
Copy Download .nbib Format: NLM
H3K27M-mutant diffuse midline gliomas should be further molecularly stratified: an integrated analysis of 669 patients.

Journal of neuro-oncology

Vuong HG, Le HT, Ngo TNM, Fung KM, Battiste JD, McNall-Knapp R, Dunn IF.
PMID: 34796414
J Neurooncol. 2021 Dec;155(3):225-234. doi: 10.1007/s11060-021-03890-9. Epub 2021 Nov 18.

INTRODUCTION: H3K27M-mutated diffuse midline gliomas (H3-DMGs) are aggressive tumors with a fatal outcome. This study integrating individual patient data (IPD) from published studies aimed to investigate the prognostic impact of different genetic alterations on survival of these patients.METHODS: We...

Cite
Vuong HG, Le HT, Ngo TNM, et al. H3K27M-mutant diffuse midline gliomas should be further molecularly stratified: an integrated analysis of 669 patients. J Neurooncol. 2021;155(3):225-234doi: 10.1007/s11060-021-03890-9.
Vuong, H. G., Le, H. T., Ngo, T. N. M., Fung, K. M., Battiste, J. D., McNall-Knapp, R., & Dunn, I. F. (2021). H3K27M-mutant diffuse midline gliomas should be further molecularly stratified: an integrated analysis of 669 patients. Journal of neuro-oncology, 155(3), 225-234. https://doi.org/10.1007/s11060-021-03890-9
Vuong, Huy Gia, et al. "H3K27M-mutant diffuse midline gliomas should be further molecularly stratified: an integrated analysis of 669 patients." Journal of neuro-oncology vol. 155,3 (2021): 225-234. doi: https://doi.org/10.1007/s11060-021-03890-9
Vuong HG, Le HT, Ngo TNM, Fung KM, Battiste JD, McNall-Knapp R, Dunn IF. H3K27M-mutant diffuse midline gliomas should be further molecularly stratified: an integrated analysis of 669 patients. J Neurooncol. 2021 Dec;155(3):225-234. doi: 10.1007/s11060-021-03890-9. Epub 2021 Nov 18. PMID: 34796414.
Copy Download .nbib Format: NLM
Selective salvage radiotherapy could provide favorable outcomes in patients with refractory or relapsed primary central nervous system lymphoma.

Journal of neuro-oncology

Kim N, Lim DH, Yoon SE, Kim SJ, Kim WS.
PMID: 34853952
J Neurooncol. 2021 Dec 01; doi: 10.1007/s11060-021-03909-1. Epub 2021 Dec 01.

INTRODUCTION: To date, there is no relevant data supporting the role of salvage radiotherapy (sRT) in patients with refractory or relapsed primary central nervous system lymphoma (PCNSL). Herein, we aimed to investigate the impact of sRT in patients with...

Cite
Kim N, Lim DH, Yoon SE, et al. Selective salvage radiotherapy could provide favorable outcomes in patients with refractory or relapsed primary central nervous system lymphoma. J Neurooncol. 2021;doi: 10.1007/s11060-021-03909-1.
Kim, N., Lim, D. H., Yoon, S. E., Kim, S. J., & Kim, W. S. (2021). Selective salvage radiotherapy could provide favorable outcomes in patients with refractory or relapsed primary central nervous system lymphoma. Journal of neuro-oncology, . https://doi.org/10.1007/s11060-021-03909-1
Kim, Nalee, et al. "Selective salvage radiotherapy could provide favorable outcomes in patients with refractory or relapsed primary central nervous system lymphoma." Journal of neuro-oncology vol. (2021). doi: https://doi.org/10.1007/s11060-021-03909-1
Kim N, Lim DH, Yoon SE, Kim SJ, Kim WS. Selective salvage radiotherapy could provide favorable outcomes in patients with refractory or relapsed primary central nervous system lymphoma. J Neurooncol. 2021 Dec 01; doi: 10.1007/s11060-021-03909-1. Epub 2021 Dec 01. PMID: 34853952.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 336 entries